Toxicological Sciences 66, 185-200 (2002)
Copyright © 2002 by the Society of Toxicology
BIOTRANSFORMATION AND TOXICOKINETICS |
Evaluation of Child/Adult Pharmacokinetic Differences from a Database Derived from the Therapeutic Drug Literature
* Connecticut Department of Public Health, P.O. Box 340308, Mail Stop 11CHA, Hartford, Connecticut 06134;
Clark University, Center for Technology, Environment & Development, Worcester, Massachusetts; and
National Center for Environmental Assessment, Research and Development, U.S. EPA, Washington, DC
Pharmacokinetics (PK) of xenobiotics can differ widely between children and adults due to physiological differences and the immaturity of enzyme systems and clearance mechanisms. This makes extrapolation of adult dosimetry estimates to children uncertain, especially at early postnatal ages. While there is very little PK data for environmental toxicants in children, there is a wealth of such data for therapeutic drugs. Using published literature, a Children's PK Database has been compiled which compares PK parameters between children and adults for 45 drugs. This has enabled comparison of child and adult PK function across a number of cytochrome P450 (CYP) pathways, as well as certain Phase II conjugation reactions and renal elimination. These comparisons indicate that premature and full-term neonates tend to have 3 to 9 times longer half-life than adults for the drugs included in the database. This difference disappears by 2–6 months of age. Beyond this age, half-life can be shorter than in adults for specific drugs and pathways. The range of neonate/adult half-life ratios exceeds the 3.16-fold factor commonly ascribed to interindividual PK variability. Thus, this uncertainty factor may not be adequate for certain chemicals in the early postnatal period. The current findings present a PK developmental profile that is relevant to environmental toxicants metabolized and cleared by the pathways represented in the current database. The manner in which this PK information can be applied to the risk assessment of children includes several different approaches: qualitative (e.g., enhanced discussion of uncertainties), semiquantitative (age group-specific adjustment factors), and quantitative (estimation of internal dosimetry in children via physiologically based PK modeling).
Key Words: children; metabolism; pharmacokinetics; risk assessment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. M. Thompson, B. Sonawane, and R. C. Grafstrom The Ontogeny, Distribution, and Regulation of Alcohol Dehydrogenase 3: Implications for Pulmonary Physiology Drug Metab. Dispos., August 1, 2009; 37(8): 1565 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Foster Therapeutic product disposition in at-risk populations Radiat Prot Dosimetry, June 1, 2009; 134(3-4): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Richardson Factors that elevate the internal radionuclide and chemical retention, dose and health risks to infants and children in a radiological-nuclear emergency Radiat Prot Dosimetry, June 1, 2009; 134(3-4): 167 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spector, A. J. Hooten, and J. A. Ross Ontogeny of Gene Expression: A Changing Environment for Malignancy Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1021 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tarning, E. A. Ashley, N. Lindegardh, K. Stepniewska, L. Phaiphun, N. P. J. Day, R. McGready, M. Ashton, F. Nosten, and N. J. White Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium falciparum Malaria in Thailand Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1052 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ritter and T. E. Arbuckle Can Exposure Characterization Explain Concurrence or Discordance between Toxicology and Epidemiology? Toxicol. Sci., June 1, 2007; 97(2): 241 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. C. M. Dorne and A. G. Renwick The Refinement of Uncertainty/Safety Factors in Risk Assessment by the Incorporation of Data on Toxicokinetic Variability in Humans Toxicol. Sci., July 1, 2005; 86(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Moser, I. Walls, and T. Zoetis Direct Dosing of Preweaning Rodents in Toxicity Testing and Research: Deliberations of an ILSI RSI Expert Working Group International Journal of Toxicology, March 1, 2005; 24(2): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Clewell, P. R. Gentry, T. R. Covington, R. Sarangapani, and J. G. Teeguarden Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry Toxicol. Sci., June 1, 2004; 79(2): 381 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ginsberg, D. Hattis, R. Miller, and B. Sonawane Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children Pediatrics, April 1, 2004; 113(4/S1): 973 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Wild and J. Kleinjans Children and Increased Susceptibility to Environmental Carcinogens: Evidence or Empathy? Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1389 - 1394. [Full Text] [PDF]
|
|